ArticleCureus2025
An Institutional Survey of Early-Onset Breast Cancer in Young Women With Imaging and Molecular Subtype Correlation.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose The burden of breast cancer in young women is high, necessitating an effective breast imaging screening protocol to decrease morbidity and mortality. This is one of the few studies conducted in India on young women with breast cancer, where we present imaging features along with proven molecular subtyping. Methods This is a retrospective study of 58 young women with biopsy-proven breast cancer between the period of January 2021 to December 2023. All imaging features were analyzed, and histopathological correlation was done. Results In our cohort, the most common age group was between 35 and 40 years. All cases underwent ultrasound, while X-ray and mammography were performed in 20 cases. Among these, three patients underwent contrast-enhanced digital mammography (CEDM), and two underwent MRI. The majority of malignancies were diagnosed as invasive mammary carcinoma. Regarding molecular subtypes, Luminal B was the most prevalent, which was a unique finding in our study, followed by triple-negative breast cancer (TNBC). Lesions with human epidermal growth factor receptor 2 (HER2)-neu and Luminal B subtypes predominantly exhibited indistinct margins, while TNBC cases commonly showed microlobulated margins. Malignant calcifications were most frequently seen in TNBC, followed by Luminal B. A one-way ANOVA demonstrated a statistically significant difference in Ki-67 levels among the subtypes. Tukey's honestly significant difference (HSD) test for multiple comparisons revealed a significant difference between Luminal B and TNBC (p < 0.05), with TNBC showing a higher Ki-67 index. The chi-square test showed a statistically significant association between molecular subtype and the presence of metastases (p < 0.05), with Luminal B more commonly associated with metastatic disease. Pregnancy-associated breast cancer (PABC) was identified in four cases, of which two had metastases, suggesting that delayed presentation is common in PABC. Multicentric malignancies were relatively more frequent in the HER2-neu subtype. Conclusion Our study reflects the increase in breast cancer and metastases in young women. The Luminal B subtype was common in our study, which was different from other studies. Metastases and PABC were higher in Luminal B. Multicentric malignancy was relatively higher in HER2-neu. However, larger multicenter studies are recommended for validating this. These observations mandate an early imaging workup to detect cancer for better survival. We also recommend screening protocols as early as 35 years, as most of the presentations were above this age in our study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.